SI1278540T1 - Uporaba inhibitorjev il-18 za zdravljenje in/ali preventivo ateroskleroze - Google Patents

Uporaba inhibitorjev il-18 za zdravljenje in/ali preventivo ateroskleroze

Info

Publication number
SI1278540T1
SI1278540T1 SI200130832T SI200130832T SI1278540T1 SI 1278540 T1 SI1278540 T1 SI 1278540T1 SI 200130832 T SI200130832 T SI 200130832T SI 200130832 T SI200130832 T SI 200130832T SI 1278540 T1 SI1278540 T1 SI 1278540T1
Authority
SI
Slovenia
Prior art keywords
atherosclerosis
inhibitors
prevention
treatment
Prior art date
Application number
SI200130832T
Other languages
English (en)
Inventor
Yolande Chvatchko
Alain Tedgui
Ziad Mallat
Original Assignee
Edicale Inserm Inst Nat De La
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edicale Inserm Inst Nat De La, Serono Lab filed Critical Edicale Inserm Inst Nat De La
Publication of SI1278540T1 publication Critical patent/SI1278540T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SI200130832T 2000-05-05 2001-04-30 Uporaba inhibitorjev il-18 za zdravljenje in/ali preventivo ateroskleroze SI1278540T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00109606 2000-05-05
PCT/EP2001/004843 WO2001085201A2 (en) 2000-05-05 2001-04-30 Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
EP01945064A EP1278540B1 (en) 2000-05-05 2001-04-30 Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis

Publications (1)

Publication Number Publication Date
SI1278540T1 true SI1278540T1 (sl) 2008-10-31

Family

ID=8168631

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200130832T SI1278540T1 (sl) 2000-05-05 2001-04-30 Uporaba inhibitorjev il-18 za zdravljenje in/ali preventivo ateroskleroze

Country Status (33)

Country Link
US (1) US20040076628A1 (sl)
EP (1) EP1278540B1 (sl)
JP (1) JP5122053B2 (sl)
KR (2) KR20030016254A (sl)
CN (2) CN1250286C (sl)
AR (1) AR035640A1 (sl)
AT (1) ATE395075T1 (sl)
AU (2) AU2001267390B2 (sl)
BG (1) BG65881B1 (sl)
BR (1) BRPI0110506B8 (sl)
CA (1) CA2407895C (sl)
CY (1) CY1110385T1 (sl)
CZ (1) CZ300792B6 (sl)
DE (1) DE60134009D1 (sl)
DK (1) DK1278540T3 (sl)
EA (2) EA007014B1 (sl)
EE (1) EE05056B1 (sl)
ES (1) ES2305082T3 (sl)
HK (2) HK1055681A1 (sl)
HR (1) HRP20020828A2 (sl)
HU (1) HU229375B1 (sl)
IL (2) IL152567A0 (sl)
ME (1) ME00554B (sl)
MX (1) MXPA02010895A (sl)
NO (1) NO329821B1 (sl)
PL (1) PL209371B1 (sl)
PT (1) PT1278540E (sl)
RS (1) RS50926B (sl)
SI (1) SI1278540T1 (sl)
SK (1) SK287761B6 (sl)
UA (2) UA78492C2 (sl)
WO (1) WO2001085201A2 (sl)
ZA (1) ZA200208228B (sl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ520392A (en) * 2000-02-10 2005-04-29 Abbott Lab Antibodies that bind human interleukin-18 and methods of making and using
DE60224004T2 (de) * 2001-01-29 2009-07-23 Laboratoires Serono S.A., Coinsins Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
DK1390070T3 (en) * 2001-05-25 2017-04-24 Ares Trading Sa Use of IL-18 inhibitors to treat or prevent CNS damage
US6797727B2 (en) 2001-07-16 2004-09-28 Transition Therapeutics Inc. Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
GB0210212D0 (en) * 2002-05-03 2002-06-12 Univ Southampton Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
PT1487541E (pt) 2002-03-22 2008-12-10 Inst Nat Sante Rech Med Utilização de inibidores de il-8 para o tratamento e/ou prevenção de doenças vasculares periféricas
CN100429315C (zh) * 2003-03-11 2008-10-29 雪兰诺实验室有限公司 含有mcmv ie2启动子的表达载体
ES2384241T3 (es) 2003-05-13 2012-07-02 Merck Serono Sa Variantes activas de la proteína que fija IL-18 y usos médicos de las mismas
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
CN1997385B (zh) * 2004-04-15 2012-01-11 阿瑟拉生物技术公司 膜联蛋白v用于预防动脉血栓和斑块破裂
CN101219208B (zh) * 2005-01-04 2010-08-11 健能隆医药技术（上海）有限公司 白介素-22的医药用途
DK1885753T3 (da) 2005-06-03 2011-10-03 Ares Trading Sa Fremstilling af rekombinant II-18-proteiner
RS52273B (en) 2005-06-10 2012-10-31 Ares Trading S.A. PROCESS FOR PURIFICATION OF IL-18 BINDING PROTEIN
KR101603001B1 (ko) 2010-08-25 2016-03-11 에프. 호프만-라 로슈 아게 Il-18r1에 대한 항체 및 그의 용도
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
MD707Z (ro) * 2013-01-18 2014-07-31 Институт Зоологии Академии Наук Молдовы Metodă de identificare a secvenţelor polimorfe 4a/4b ale genei sintetazei endoteliale a oxidului nitric
WO2015032932A1 (en) 2013-09-05 2015-03-12 Ab2 Bio Sa Il-18 binding protein (il-18bp) in inflammatory diseases
BR112017017076A2 (pt) 2015-03-05 2018-04-10 Ab2 Bio Sa inibidor de il-18, anticorpo, métodos para o tratamento de uma doença ou um distúrbio associado a il-18 em um indivíduo, para determinar a quantidade de il-18 livre em uma amostra ou in situ, para diagnosticar uma predisposição a uma doença ou um distúrbio associado a il-18, para monitorar doença residual mínima em um paciente que segue o tratamento com o inibidor de il-18 ou a composição e para prever uma resposta de um paciente a um tratamento com o inibidor de il-18 ou composição, e, kit diagnóstico para detectar il-18 livre.
CN110273591B (zh) 2019-08-13 2023-12-12 上海杉脉电子科技发展有限公司 一种单动力微型智能锁
TW202233675A (zh) 2020-10-29 2022-09-01 瑞士商諾華公司 Ｉｌ－１８拮抗劑用於治療和／或預防異位性皮炎或相關病症之用途
CN112972655A (zh) * 2021-04-16 2021-06-18 武汉大学 白细胞介素12在制备预防、缓解和/或治疗主动脉瘤药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
EP0987552A3 (en) * 1998-08-31 2000-06-07 Pfizer Products Inc. Diarylsulfonylurea binding proteins
KR100537558B1 (ko) * 1998-09-01 2005-12-19 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 인터류킨-18 결합 단백질

Also Published As

Publication number Publication date
YU82602A (sh) 2006-01-16
EA005410B1 (ru) 2005-02-24
HRP20020828A2 (en) 2004-12-31
ATE395075T1 (de) 2008-05-15
BG107218A (bg) 2003-06-30
ZA200208228B (en) 2005-07-27
US20040076628A1 (en) 2004-04-22
DE60134009D1 (de) 2008-06-26
BG65881B1 (bg) 2010-04-30
EA200401183A1 (ru) 2004-12-30
WO2001085201A2 (en) 2001-11-15
AU6739001A (en) 2001-11-20
UA78492C2 (en) 2007-04-10
RS50926B (sr) 2010-08-31
KR20070073989A (ko) 2007-07-10
CA2407895C (en) 2012-12-18
AU2001267390B2 (en) 2005-09-22
EP1278540A2 (en) 2003-01-29
IL152567A (en) 2010-12-30
PL365697A1 (en) 2005-01-10
EA200201175A1 (ru) 2003-04-24
CY1110385T1 (el) 2015-04-29
NO329821B1 (no) 2010-12-27
CN1841066A (zh) 2006-10-04
BRPI0110506B8 (pt) 2021-05-25
HUP0301991A2 (hu) 2003-09-29
UA87658C2 (uk) 2009-08-10
NO20025307L (no) 2002-12-18
CZ20023644A3 (cs) 2003-03-12
ME00554B (me) 2012-03-20
BR0110506A (pt) 2003-04-01
IL152567A0 (en) 2003-05-29
CZ300792B6 (cs) 2009-08-12
BRPI0110506B1 (pt) 2015-05-19
JP5122053B2 (ja) 2013-01-16
MEP64008A (en) 2011-12-20
AR035640A1 (es) 2004-06-23
KR100798545B1 (ko) 2008-01-28
CN1841066B (zh) 2012-08-29
CN1250286C (zh) 2006-04-12
SK15562002A3 (sk) 2003-05-02
EE200200620A (et) 2004-06-15
JP2003532685A (ja) 2003-11-05
CN1434722A (zh) 2003-08-06
HU229375B1 (en) 2013-11-28
KR20030016254A (ko) 2003-02-26
WO2001085201A3 (en) 2002-05-10
MXPA02010895A (es) 2003-03-27
PL209371B1 (pl) 2011-08-31
ES2305082T3 (es) 2008-11-01
SK287761B6 (en) 2011-09-05
EA007014B1 (ru) 2006-06-30
EP1278540B1 (en) 2008-05-14
HUP0301991A3 (en) 2006-11-28
HK1055681A1 (en) 2004-01-21
NO20025307D0 (no) 2002-11-05
CA2407895A1 (en) 2001-11-15
HK1094909A1 (en) 2007-04-13
DK1278540T3 (da) 2008-07-21
EE05056B1 (et) 2008-08-15
PT1278540E (pt) 2008-07-03

Similar Documents

Publication Publication Date Title
HK1094909A1 (en) Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis il-18
AU8870701A (en) Materials and methods for the treatment or prevention of obesity
HK1061851A1 (en) Gyrase inhibitors and uses thereof
PL364995A1 (en) Method for the treatment or prevention of flavivirus
PL357713A1 (en) Caspase inhibitors and uses thereof
HK1053984B (zh) 回旋酶抑制劑及其用途
AU5714601A (en) Methods for prevention and treatment of gastrointestinal disorders
PL356066A1 (en) Caspase inhibitors and uses thereof
GB0025782D0 (en) Use of inhibitors
IL146000A0 (en) Ace-2 inhibiting compounds and methods of use thereof
EP1423081A4 (en) COMPOSITION COMPRISING GLYCOSAMINOGLYCANS AND HYALURONIDASE INHIBITORS FOR THE TREATMENT OF ARTHRITIC ARTICULATIONS
EP1337255A4 (en) USE OF P38 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY COUGH
EP1239855A4 (en) METHOD FOR PREVENTING AND TREATING ARTERIOSCLEROSIS
HK1062810A1 (en) Use of il-18 inhibitors for the manufacture of medicaments for treatment and/or prevention of heartdisease
EP1309552A4 (en) COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES
HUP0302738A3 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
HK1069762A1 (en) Use of il-18 inhibitors for treating or preventingcns injuries
IL154927A0 (en) Combination of statins and sorbitol dehydrogenase inhibitors
AU2002222125A1 (en) Prevention and treatment of tachyphylactic response
EP1305017A4 (en) METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF SYNDROME X
IL165870A0 (en) Use of chymase inhibitors for the prevention and/or
GB0119460D0 (en) The use of inhibitors of the renin-angiotensin system
IL143903A0 (en) Use of phanquinone for the treatment or prevention of memory impairment
AU7223401A (en) Compounds and inhibitors of phospholipases
GB0030867D0 (en) Treatment and prevention of tissue damage